Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability

Janssen Has First Combo Data, With Its Own Darzalex

Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.

Galloping jockeys and race horse toys competing for position — T-cell-recruiting bispecific antibodies are jockeying for position in multiple myeloma • Source: Alamy

Bispecific antibodies that redirect T-cells to cancer cells expressing a targeted antigen are showing impressive responses in relapsed and refractory multiple myeloma, but to date there has been little data to separate the winners from the losers. Updates at the American Society of Hematology (ASH) meeting did little to move the needle in any one bispecific antibody’s favor, but presentations during the meeting offered data and insights into how companies aim to stand out in this increasingly crowded field.

Speed of clinical trial program execution will be an important factor, as well as safety, given the cytokine-release syndrome (CRS)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

09 Jun 2025

• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

09 Jun 2025

• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Pipeline Watch: ASCO Dominates Phase III Readouts

09 Jun 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

09 Jun 2025

• By Ian Haydock

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.